Top-Rated StocksTop-RatedNASDAQ:JANX Janux Therapeutics (JANX) Stock Price, News & Analysis $22.58 -1.60 (-6.62%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$22.99 +0.41 (+1.82%) As of 04:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Janux Therapeutics Stock (NASDAQ:JANX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Janux Therapeutics alerts:Sign Up Key Stats Today's Range$22.50▼$24.6750-Day Range$22.58▼$27.7552-Week Range$22.48▼$71.71Volume1.22 million shsAverage Volume857,433 shsMarket Capitalization$1.34 billionP/E RatioN/ADividend YieldN/APrice Target$91.89Consensus RatingBuy Company Overview Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. Read More Janux Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreJANX MarketRank™: Janux Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 598th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingJanux Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageJanux Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Janux Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.38) to ($2.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Janux Therapeutics is -16.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Janux Therapeutics is -16.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJanux Therapeutics has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.48% of the float of Janux Therapeutics has been sold short.Short Interest Ratio / Days to CoverJanux Therapeutics has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in Janux Therapeutics has recently decreased by 5.95%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJanux Therapeutics does not currently pay a dividend.Dividend GrowthJanux Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.48% of the float of Janux Therapeutics has been sold short.Short Interest Ratio / Days to CoverJanux Therapeutics has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in Janux Therapeutics has recently decreased by 5.95%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.70 News SentimentJanux Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Janux Therapeutics this week, compared to 5 articles on an average week.Search Interest4 people have searched for JANX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows5 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Janux Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.10% of the stock of Janux Therapeutics is held by insiders.Percentage Held by Institutions75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Janux Therapeutics' insider trading history. Receive JANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address JANX Stock News HeadlinesJanux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With MerckAugust 5 at 4:05 PM | businesswire.comJanux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In CashJuly 31, 2025 | seekingalpha.comTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative... | InvestorPlace (Ad)Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D DayJuly 24, 2025 | businesswire.comJanux Therapeutics to Host Virtual R&D Day on July 24, 2025July 17, 2025 | businesswire.comRaymond James Initiates Coverage of Janux Therapeutics (JANX) with Outperform RecommendationJuly 12, 2025 | msn.comJanux Therapeutics Inc Ordinary Shares JANX - MorningstarJune 27, 2025 | morningstar.comMJonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price TargetJune 24, 2025 | msn.comSee More Headlines JANX Stock Analysis - Frequently Asked Questions How have JANX shares performed this year? Janux Therapeutics' stock was trading at $53.54 at the beginning of 2025. Since then, JANX shares have decreased by 57.8% and is now trading at $22.58. How were Janux Therapeutics' earnings last quarter? Janux Therapeutics, Inc. (NASDAQ:JANX) announced its earnings results on Thursday, August, 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.05. When did Janux Therapeutics IPO? Janux Therapeutics (JANX) raised $152 million in an IPO on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager. Who are Janux Therapeutics' major shareholders? Top institutional investors of Janux Therapeutics include Aberdeen Group plc (0.48%), TD Asset Management Inc (0.11%), Atle Fund Management AB (0.08%) and Y Intercept Hong Kong Ltd (0.03%). Insiders that own company stock include Ra Capital Management, LP, Tighe Reardon, David Alan Campbell, Andrew Hollman Meyer and Ventures Xi LP Avalon. View institutional ownership trends. How do I buy shares of Janux Therapeutics? Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Janux Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Janux Therapeutics investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), Waste Connections (WCN) and AU Optronics (AUOTY). Company Calendar Last Earnings8/07/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JANX CIK1817713 Webwww.januxrx.com Phone858-751-4493FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Janux Therapeutics$91.89 High Price Target$200.00 Low Price Target$41.00 Potential Upside/Downside+306.9%Consensus RatingBuy Rating Score (0-4)3.08 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$68.99 million Net MarginsN/A Pretax Margin-832.71% Return on Equity-9.29% Return on Assets-8.89% Debt Debt-to-Equity RatioN/A Current Ratio58.47 Quick Ratio58.47 Sales & Book Value Annual Sales$9.34 million Price / Sales143.12 Cash FlowN/A Price / Cash FlowN/A Book Value$19.49 per share Price / Book1.16Miscellaneous Outstanding Shares59,175,000Free Float54,382,000Market Cap$1.34 billion OptionableOptionable Beta2.86 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:JANX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.